Edition:
United Kingdom

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

5.50USD
24 Apr 2018
Change (% chg)

$0.05 (+0.92%)
Prev Close
$5.45
Open
$5.45
Day's High
$5.65
Day's Low
$5.40
Volume
30,175
Avg. Vol
51,066
52-wk High
$8.25
52-wk Low
$3.20

Chart for

About

Arbutus Biopharma Corp is a Canada-based company engaged in biopharmaceutical sector. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company is focused on a process of... (more)
No analyst recommendations are available for .

Overall

Beta: 0.72
Market Cap(Mil.): $493.14
Shares Outstanding(Mil.): 55.03
Dividend: --
Yield (%): --

Financials

  ABUS.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.15 -- --
ROI: -51.57 14.84 14.38
ROE: -55.72 16.34 16.07

BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology

* ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY

22 Feb 2018

BRIEF-Arbutus Enters Exclusivity Agreement With Roivant Sciences

* ARBUTUS ENTERS EXCLUSIVITY AGREEMENT WITH ROIVANT SCIENCES Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

15 Feb 2018

BRIEF-Arbutus Announces Departure Of CFO Bruce Cousins

* ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO

14 Feb 2018

BRIEF-Arbutus Consolidates HBV Business Around Warminster, PA Site

* ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA

08 Feb 2018

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

16 Nov 2017

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency

* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

13 Nov 2017

BRIEF-Arbutus Biopharma reports Q3 loss per share $0.21

* Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results

02 Nov 2017

Earnings vs. Estimates